{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:39:25Z","timestamp":1791283165482,"version":"4.1.0"},"reference-count":108,"publisher":"CSIRO Publishing","issue":"4","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":5145,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,9]]},"abstract":"<jats:p>In the developed world, HIV infection is now well managed with very effective and less toxic antiretroviral treatment. HIV-positive patients therefore are living longer, but are now faced by challenges associated with aging. Several non-AIDS associated morbidities are increased in this population, including cardiovascular disease (CVD). It is suggested that CVD occurs earlier among HIV-positive patients compared with HIV-negative patients, and at a higher rate. Several factors have been proposed to contribute to this. First, the traditional CVD risk factors are highly prevalent in this population. High rates of smoking, dyslipidaemia and a family history of CVD have been reported. This population is also aging, with estimates of more than 25% of HIV-positive patients in the developed world being over the age of 50. Antiretroviral treatment, both through its effect on lipids and through other, sometimes less well understood, mechanisms, has been linked to increased CVD risk. HIV infection, especially untreated, is a further contributing factor to increased CVD risk in HIV-positive patients. As the HIV-positive population continues to age, the risk of CVD will continue to increase. Guidelines for the management and prevention of CVD risk have been developed, and are largely modelled on those used in the general population. However, the data currently suggest that these interventions, such as the use of lipid-lowering medications and smoking cessation programs, remain quite low. A better understanding the mechanisms of CVD risk in this aging population and further efforts in improving uptake of prevention strategies will remain an important research area.<\/jats:p>","DOI":"10.1071\/sh11020","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T23:38:50Z","timestamp":1320795530000},"page":"465-473","source":"Crossref","is-referenced-by-count":22,"title":["HIV infection, aging and cardiovascular disease: epidemiology and prevention"],"prefix":"10.1071","volume":"8","author":[{"given":"Kathy","family":"Petoumenos","sequence":"first","affiliation":[{"name":"AThe Kirby Institute, University of New South Wales, Sydney, NSW 2010, Australia."},{"name":"CCorresponding author. Email: Kpetoumenos@kirby.unsw.edu.au"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe W.","family":"Worm","sequence":"additional","affiliation":[{"name":"BCopenhagen HIV Program (CHIP), University of Copenhagen, Copenhagen DK-2200, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2011,7,29]]},"reference":[{"key":"2025102617005369700_R1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1468-1293.2006.00362.x","article-title":"The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study.","volume":"7","author":"Law","year":"2006","journal-title":"HIV Med"},{"key":"2025102617005369700_R2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1258\/095646205774357398","article-title":"Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study).","volume":"16","author":"Santos","year":"2005","journal-title":"Int J STD AIDS"},{"key":"2025102617005369700_R3","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1086\/521935","article-title":"Ten-year predicted coronary heart disease risk in HIV-infected men and women.","volume":"45","author":"Kaplan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1468-1293.2006.00400.x","article-title":"Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study.","volume":"7","author":"Glass","year":"2006","journal-title":"HIV Med"},{"key":"2025102617005369700_R5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1086\/528862","article-title":"Data Collections on Adverse Events of Anti-HIV Drugs Study Group. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.","volume":"46","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1071\/SH08063","article-title":"Rapidly ageing HIV epidemic among men who have sex with men in Australia.","volume":"6","author":"Murray","year":"2009","journal-title":"Sex Health"},{"key":"2025102617005369700_R7"},{"key":"2025102617005369700_R8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1086\/590150","article-title":"Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.","volume":"47","author":"Effros","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R9","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.","volume":"92","author":"Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102617005369700_R10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00126334-200308010-00012","article-title":"Coronary heart disease in HIV-infected individuals.","volume":"33","author":"Currier","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102617005369700_R11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00126334-200208150-00002","article-title":"Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?","volume":"30","author":"Klein","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102617005369700_R12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1086\/375844","article-title":"Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.","volume":"37","author":"Saves","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R13"},{"key":"2025102617005369700_R14","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/j.1743-6109.2009.01323.x","article-title":"Use of illicit drugs and erectile dysfunction medications and subsequent HIV infection among gay men in Sydney, Australia.","volume":"6","author":"Prestage","year":"2009","journal-title":"J Sex Med"},{"key":"2025102617005369700_R15","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1086\/652749","article-title":"Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.","volume":"201","author":"Neuhaus","year":"2010","journal-title":"J Infect Dis"},{"key":"2025102617005369700_R16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"The D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction.","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"2025102617005369700_R17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"The D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"2025102617005369700_R18","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"The Strategies of Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment.","volume":"355","year":"2006","journal-title":"N Engl J Med"},{"key":"2025102617005369700_R19","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction.","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"2025102617005369700_R20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/QAD.0b013e328339192f","article-title":"Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population.","volume":"24","author":"Lang","year":"2010","journal-title":"AIDS"},{"key":"2025102617005369700_R21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients \u2013 association with antiretroviral therapy. Results from the D:A:D study.","volume":"17","author":"Friis-Moller","year":"2003","journal-title":"AIDS"},{"key":"2025102617005369700_R22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1468-1293.2004.00191.x","article-title":"Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population.","volume":"5","author":"Smith","year":"2004","journal-title":"HIV Med"},{"key":"2025102617005369700_R23","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1161\/CIRCULATIONAHA.107.189624","article-title":"Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.","volume":"118","author":"Currier","year":"2008","journal-title":"Circulation"},{"key":"2025102617005369700_R24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1468-1293.2005.00265.x","article-title":"Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.","volume":"6","author":"Iloeje","year":"2005","journal-title":"HIV Med"},{"key":"2025102617005369700_R25"},{"key":"2025102617005369700_R26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1089\/apc.2006.0142","article-title":"Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine cohort.","volume":"21","author":"Benard","year":"2007","journal-title":"AIDS Patient Care STDS"},{"key":"2025102617005369700_R27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/135965350801300305","article-title":"Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study.","volume":"13","author":"Duval","year":"2008","journal-title":"Antivir Ther"},{"key":"2025102617005369700_R28","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10461-008-9449-2","article-title":"Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation.","volume":"14","author":"Tesoriero","year":"2008","journal-title":"AIDS Behav"},{"key":"2025102617005369700_R29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/108729102753429389","article-title":"Cigarette smoking and the desire to quit among individuals living with HIV.","volume":"16","author":"Mamary","year":"2002","journal-title":"AIDS Patient Care STDS"},{"key":"2025102617005369700_R30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11606-007-0158-8","article-title":"Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans.","volume":"22","author":"Crothers","year":"2007","journal-title":"J Gen Intern Med"},{"key":"2025102617005369700_R31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2010.00901.x","article-title":"Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study.","author":"Petoumenos","year":"2011","journal-title":"HIV Med"},{"key":"2025102617005369700_R32","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.2105\/AJPH.2009.188664","article-title":"Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial.","volume":"100","author":"Lifson","year":"2010","journal-title":"Am J Public Health"},{"key":"2025102617005369700_R33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJM200108023450507","article-title":"Cardiovascular complications of cocaine use.","volume":"345","author":"Lange","year":"2001","journal-title":"N Engl J Med"},{"key":"2025102617005369700_R34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1086\/526782","article-title":"Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms.","volume":"46","author":"Lai","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R35","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1097\/QAD.0b013e32830507f2","article-title":"Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women.","volume":"22","author":"Cook","year":"2008","journal-title":"AIDS"},{"key":"2025102617005369700_R36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00042560-200107010-00006","article-title":"Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.","volume":"27","author":"Lucas","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102617005369700_R37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/135965350501000706","article-title":"Predictors of hypertension and changes of blood pressure in HIV-infected patients.","volume":"10","author":"Thiebaut","year":"2005","journal-title":"Antivir Ther"},{"key":"2025102617005369700_R38","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/dc07-2013","article-title":"Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.","volume":"31","author":"De Wit","year":"2008","journal-title":"Diabetes Care"},{"key":"2025102617005369700_R39","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1161\/CIRCULATIONAHA.108.790857","article-title":"Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).","volume":"119","author":"Worm","year":"2009","journal-title":"Circulation"},{"key":"2025102617005369700_R40","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.","volume":"100","author":"Periard","year":"1999","journal-title":"Circulation"},{"key":"2025102617005369700_R41","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men.","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"2025102617005369700_R42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0924-8579(03)00100-6","article-title":"Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.","volume":"22","author":"Calza","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"2025102617005369700_R43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1210\/jc.74.5.1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102617005369700_R44","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/S0140-6736(01)06413-3","article-title":"Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.","volume":"358","author":"Fellay","year":"2001","journal-title":"Lancet"},{"key":"2025102617005369700_R45","doi-asserted-by":"publisher","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"2025102617005369700_R46","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"2025102617005369700_R47","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"2025102617005369700_R48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1468-1293.2005.00269.x","article-title":"Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study.","volume":"6","author":"Richter","year":"2005","journal-title":"HIV Med"},{"key":"2025102617005369700_R50","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1097\/QAD.0b013e328300581d","article-title":"Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.","volume":"22","author":"Kaplan","year":"2008","journal-title":"AIDS"},{"key":"2025102617005369700_R51","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","article-title":"Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.","volume":"17","author":"Mary-Krause","year":"2003","journal-title":"AIDS"},{"key":"2025102617005369700_R52","article-title":"Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system.","author":"Triant","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102617005369700_R53","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1086\/655144","article-title":"Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.","volume":"51","author":"Lichtenstein","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R54","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1468-1293.2007.00508.x","article-title":"Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine cohort, 2000\u20132004.","volume":"8","author":"Bonnet","year":"2007","journal-title":"HIV Med"},{"key":"2025102617005369700_R55","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1097\/QAD.0b013e32832e9b78","article-title":"Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.","volume":"23","author":"Marin","year":"2009","journal-title":"AIDS"},{"key":"2025102617005369700_R56","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease.","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"2025102617005369700_R57","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.amjmed.2008.06.012","article-title":"Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective.","volume":"121","author":"Wilson","year":"2008","journal-title":"Am J Med"},{"key":"2025102617005369700_R58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2174\/157016210791330419","article-title":"Both HIV-infection and long-term antiretroviral therapy are associated with increased common carotid intima\u2013media thickness in HIV-infected adolescents and young adults.","volume":"8","author":"Vigano","year":"2010","journal-title":"Curr HIV Res"},{"key":"2025102617005369700_R59","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1086\/605578","article-title":"Relationship between inflammatory markers, endothelial activation markers, and carotid intima\u2013media thickness in HIV-infected patients receiving antiretroviral therapy.","volume":"49","author":"Ross","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R60","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1161\/01.CIR.0000124480.32233.8A","article-title":"Progression of atherosclerosis as assessed by carotid intima\u2013media thickness in patients with HIV infection.","volume":"109","author":"Hsue","year":"2004","journal-title":"Circulation"},{"key":"2025102617005369700_R61","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1210\/jc.2006-1140","article-title":"Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome.","volume":"91","author":"Johnsen","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102617005369700_R62","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/QAD.0b013e32811ebf79","article-title":"Progression of carotid artery intima\u2013media thickening in HIV-infected and uninfected adults.","volume":"21","author":"Currier","year":"2007","journal-title":"AIDS"},{"key":"2025102617005369700_R63","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"key":"2025102617005369700_R64","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1371\/journal.pmed.0050078","article-title":"Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review.","volume":"5","author":"Danesh","year":"2008","journal-title":"PLoS Med"},{"key":"2025102617005369700_R65","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archinte.166.1.64","article-title":"C-reactive protein is a marker for human immunodeficiency virus disease progression.","volume":"166","author":"Lau","year":"2006","journal-title":"Arch Intern Med"},{"key":"2025102617005369700_R66","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.103.19.2323","article-title":"Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis.","volume":"103","author":"Danesh","year":"2001","journal-title":"Circulation"},{"key":"2025102617005369700_R67","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.","volume":"5","author":"Kuller","year":"2008","journal-title":"PLoS Med"},{"key":"2025102617005369700_R68","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2008.02.003","article-title":"High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection.","volume":"201","author":"Guimaraes","year":"2008","journal-title":"Atherosclerosis"},{"key":"2025102617005369700_R69","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/QAD.0b013e3282f560d9","article-title":"Association of antiretroviral therapy with fibrinogen levels in HIV-infection.","volume":"22","author":"Madden","year":"2008","journal-title":"AIDS"},{"key":"2025102617005369700_R70","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1086\/375372","article-title":"Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes.","volume":"187","author":"Kalayjian","year":"2003","journal-title":"J Infect Dis"},{"key":"2025102617005369700_R71","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.exger.2006.12.003","article-title":"Accelerated immune senescence and HIV-1 infection.","volume":"42","author":"Appay","year":"2007","journal-title":"Exp Gerontol"},{"key":"2025102617005369700_R72","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.imlet.2004.10.003","article-title":"Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system.","volume":"97","author":"van Baarle","year":"2005","journal-title":"Immunol Lett"},{"key":"2025102617005369700_R73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/135965350801300215","article-title":"Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.","volume":"13","author":"Phillips","year":"2008","journal-title":"Antivir Ther"},{"key":"2025102617005369700_R74","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(02)11672-2","article-title":"Protease inhibitors and cardiovascular outcomes in patients with HIV-1.","volume":"360","author":"Holmberg","year":"2002","journal-title":"Lancet"},{"key":"2025102617005369700_R75","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/archinternmed.2010.197","article-title":"Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.","volume":"170","author":"Lang","year":"2010","journal-title":"Arch Intern Med"},{"key":"2025102617005369700_R76","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"key":"2025102617005369700_R77","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"2025102617005369700_R78","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.","volume":"22","author":"Strategies for Management of Anti-Retroviral Therapy\/INSIGHT, D:A:D Study Groups.","year":"2008","journal-title":"AIDS"},{"key":"2025102617005369700_R79","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1468-1293.2009.00751.x","article-title":"Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.","volume":"11","author":"Obel","year":"2010","journal-title":"HIV Med"},{"key":"2025102617005369700_R80","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial.","volume":"49","author":"Martin","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R81","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/QAI.0b013e31819ff0e6","article-title":"Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.","volume":"51","author":"Brothers","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102617005369700_R82"},{"key":"2025102617005369700_R83","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/cid\/ciq244","article-title":"No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001\/ALLRT.","volume":"52","author":"Ribaudo","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R84","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/QAD.0b013e328336098c","article-title":"Platelet function and HIV: a case-control study.","volume":"24","author":"Satchell","year":"2010","journal-title":"AIDS"},{"key":"2025102617005369700_R85"},{"key":"2025102617005369700_R86","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/QAD.0b013e32833a2b02","article-title":"Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation.","volume":"24","author":"De Pablo","year":"2010","journal-title":"AIDS"},{"key":"2025102617005369700_R87","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/QAI.0b013e3181f7f61a","article-title":"Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.","volume":"56","author":"Baker","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025102617005369700_R88","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/HJR.0b013e328336a150","article-title":"Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.","volume":"17","author":"Friis-Moller","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2025102617005369700_R89","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/ije\/dym135","article-title":"A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men.","volume":"36","author":"May","year":"2007","journal-title":"Int J Epidemiol"},{"key":"2025102617005369700_R90","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1086\/378131","article-title":"Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.","volume":"37","author":"Dube","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R91","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III.)","volume":"285","author":"ATP-III Panel.","year":"2001","journal-title":"JAMA"},{"key":"2025102617005369700_R92","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","article-title":"European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.","volume":"9","author":"Lundgren","year":"2008","journal-title":"HIV Med"},{"key":"2025102617005369700_R93","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1086\/521936","article-title":"Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools?","volume":"45","author":"Friis-Moller","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2025102617005369700_R94","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jinf.2003.09.006","article-title":"Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.","volume":"49","author":"Visnegarwala","year":"2004","journal-title":"J Infect"},{"key":"2025102617005369700_R95","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1468-1293.2007.00449.x","article-title":"Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets.","volume":"8","author":"Norm\u00e9n","year":"2007","journal-title":"HIV Med"},{"key":"2025102617005369700_R96","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1089\/aid.2005.21.757","article-title":"A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.","volume":"21","author":"Aberg","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025102617005369700_R97","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/01.aids.0000244203.95758.db","article-title":"Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome.","volume":"20","author":"Fitch","year":"2006","journal-title":"AIDS"},{"key":"2025102617005369700_R98","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jama.1988.03720070025028","article-title":"Cigarette smoking as a risk factor for stroke. The Framingham Study.","volume":"259","author":"Wolf","year":"1988","journal-title":"JAMA"},{"key":"2025102617005369700_R99","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jama.1995.03530020073035","article-title":"Smoking cessation and the risk of stroke in middle-aged men.","volume":"274","author":"Wannamethee","year":"1995","journal-title":"JAMA"},{"key":"2025102617005369700_R100","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/0895-4356(93)90025-V","article-title":"Mortality in relation to smoking history: 13 years\u2019 follow-up of 68,000 Norwegian men and women 35\u201349 years.","volume":"46","author":"Tverdal","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"2025102617005369700_R101","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJM198512123132404","article-title":"The risk of myocardial infarction after quitting smoking in men under 55 years of age.","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"2025102617005369700_R102","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/aje\/kwf150","article-title":"Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies.","volume":"156","author":"Godtfredsen","year":"2002","journal-title":"Am J Epidemiol"},{"key":"2025102617005369700_R103","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1136\/bmj.38142.554479.AE","article-title":"Mortality in relation to smoking: 50 years\u2019 observations on male British doctors.","volume":"328","author":"Doll","year":"2004","journal-title":"BMJ"},{"key":"2025102617005369700_R104","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/j.1360-0443.2009.02623.x","article-title":"Motivation and patch treatment for HIV+ smokers: a randomized controlled trial.","volume":"104","author":"Lloyd-Richardson","year":"2009","journal-title":"Addiction"},{"key":"2025102617005369700_R105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7748\/ns.20.12.41.s56","article-title":"Smoking cessation for clients who are HIV-positive.","volume":"20","author":"Cummins","year":"2005","journal-title":"Nurs Stand"},{"key":"2025102617005369700_R106","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/135965350601100611","article-title":"A smoking cessation programme in HIV-infected individuals: a pilot study.","volume":"11","author":"Elzi","year":"2006","journal-title":"Antivir Ther"},{"key":"2025102617005369700_R107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1055-3290(06)60353-1","article-title":"The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers.","volume":"11","author":"Wewers","year":"2000","journal-title":"J Assoc Nurses AIDS Care"},{"key":"2025102617005369700_R108","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1086\/314048","article-title":"Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now.","volume":"31","author":"Niaura","year":"2000","journal-title":"Clin Infect Dis"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/8\/4\/465\/1253820\/sh11020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/8\/4\/465\/1253820\/sh11020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:01:00Z","timestamp":1761512460000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/8\/4\/465\/184721\/HIV-infection-aging-and-cardiovascular-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,29]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,11,9]]}},"URL":"https:\/\/doi.org\/10.1071\/sh11020","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,29]]}}}